Proteostasis Therapeutics Inc (NASDAQ:PTI) Short Interest Update

Proteostasis Therapeutics Inc (NASDAQ:PTI) was the target of a large decrease in short interest in September. As of September 30th, there was short interest totalling 2,530,000 shares, a decrease of 8.7% from the August 30th total of 2,770,000 shares. Based on an average daily volume of 417,000 shares, the days-to-cover ratio is presently 6.1 days. Currently, 7.0% of the company’s stock are short sold.

Large investors have recently added to or reduced their stakes in the business. Paloma Partners Management Co acquired a new position in Proteostasis Therapeutics during the 2nd quarter worth approximately $150,000. Jane Street Group LLC boosted its holdings in shares of Proteostasis Therapeutics by 445.5% in the 2nd quarter. Jane Street Group LLC now owns 175,050 shares of the company’s stock valued at $171,000 after buying an additional 142,958 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Proteostasis Therapeutics in the 2nd quarter valued at approximately $178,000. A.R.T. Advisors LLC acquired a new stake in shares of Proteostasis Therapeutics in the 2nd quarter valued at approximately $189,000. Finally, Acadian Asset Management LLC boosted its holdings in shares of Proteostasis Therapeutics by 61.7% in the 2nd quarter. Acadian Asset Management LLC now owns 373,324 shares of the company’s stock valued at $365,000 after buying an additional 142,446 shares during the last quarter. 44.64% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:PTI traded down $0.01 during trading hours on Tuesday, reaching $0.77. 8,102 shares of the stock were exchanged, compared to its average volume of 305,197. Proteostasis Therapeutics has a twelve month low of $0.61 and a twelve month high of $10.38. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.19 and a quick ratio of 8.19. The firm has a 50 day moving average of $0.84 and a 200 day moving average of $0.97. The stock has a market cap of $40.38 million, a PE ratio of -0.49 and a beta of -0.58.

Proteostasis Therapeutics (NASDAQ:PTI) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.01). Equities research analysts anticipate that Proteostasis Therapeutics will post -1.49 earnings per share for the current year.

A number of analysts recently issued reports on the company. ValuEngine raised Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright reissued a “buy” rating on shares of Proteostasis Therapeutics in a research note on Friday, August 9th. Finally, Zacks Investment Research cut Proteostasis Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 10th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Proteostasis Therapeutics presently has an average rating of “Hold” and an average target price of $8.75.

Proteostasis Therapeutics Company Profile

Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.

Featured Article: The role of implied volatility with call option volume

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.